NYMUSA 20mg / ml infusion solution / oral solution medication leaflet

N06BC01 • caffeine citrate • Nervous system | Psychostimulants, agents used for adhd and nootropics | Xanthine derivatives

Cafeinum citrat is a medication primarily used for the treatment of apnea of prematurity in newborns, a condition characterized by breathing pauses due to the immaturity of the central nervous system. Caffeine acts as a central nervous system stimulant, improving respiratory control and reducing the frequency of apnea episodes.

The medication is administered orally or intravenously, as directed by a doctor. The dosage is adjusted based on the newborn's body weight and response to treatment.

Common side effects include irritability, tachycardia, gastroesophageal reflux, and sleep disturbances. In rare cases, more severe adverse effects such as seizures or severe arrhythmias may occur.

Cafeinum citrat should be used with caution in newborns with cardiac conditions or other medical issues. Careful monitoring of vital signs and serum caffeine levels is essential to prevent toxicity. Additionally, parents should be informed about potential side effects and report any changes in the child's condition to the healthcare provider.